# INTERVIEW: Northland Capital Vadim Alexandre on ImmuPhrama Plc Phase III trial update

- Link: https://www.directorstalkinterviews.com/northland-capital-vadim-alexandre-immuphrama-plc-phase-iii-trial-update/412722315
- Published: 2017-01-26T07:57:02+00:00
- Author: Giles Arbor

Northland Capital Partners Head of research Vadim Alexandre talks to DirectorsTalk
about the phase III trial update announced by** Immupharma Plc** (LON:IMM). Vadim
talks us through the highlights and the keys points to take away from this update.

Vadim has over a decade of capital markets experience, specialising in the healthcare
sector. He joins Northland from Daniel Stewart & Company plc, where he headed the
research department and developed a leading healthcare franchise for the firm.

ImmuPharma Plc is a pharmaceutical development company listed since 2006 on AIM 
of the London Stock Exchange, focusing on developing novel medicines with high sales
potential in specialist markets with serious unmet need. The company is led by a
commercially focused Board and management team with extensive experience. Lupuzor
^(™) (also referred to as Forigerimod, or P140) is ImmuPharma’s lead compound and
a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially
life-threatening auto-immune disease. Lupuzor^(™)has a novel mechanism of action
aimed at modulating the body’s immune system so that it does not attack healthy 
cells, and avoids causing adverse side effects.  It has the potential to halt the
progression of the disease in a substantial proportion of patients.

Share on: